uniQure Reports 52-Week Clinical Data of Etranacogene Dezaparvovec in P-III HOPE-B Trial for Hemophilia B

 uniQure Reports 52-Week Clinical Data of Etranacogene Dezaparvovec in P-III HOPE-B Trial for Hemophilia B

uniQure Reports 52-Week Clinical Data of Etranacogene Dezaparvovec in P-III HOPE-B Trial for Hemophilia B

Shots:

  • The P- III HOPE-B gene therapy trial involves assessing etranacogene dezaparvovec in 54 patients with severe and moderately hemophilia B
  • The results showed that the patients achieved sustained increases in FIX activity @ 1 yr. post-infusion with a mean FIX activity of 41.5% compared to 39.0% @ 26-wks of follow-up, reduced the ABR by 80% from 3.39 at baseline to 0.68 bleeds & 85% from 1.16 at baseline to 0.18 bleeds/yr from single-dose @ 1 yr. & generally well-tolerated with no treatment-related AEs
  • uniQure to conduct 1EPs analysis of ABR @78 wks. after the administration and expects to complete at the end of Q3’21 while UniQure & CSL Behring expects to submit the BLA in Q1’22

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Het Financieele Dagblad

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post